InterCure Ltd. reported preliminary 2025 revenues of NIS 265 million, reflecting 11% year-over-year growth driven by accelerating momentum in the second half of the year, which generated nearly 20% growth compared to the prior-year period. The Israeli cannabis company achieved positive Adjusted EBITDA for the twelfth consecutive half-year, demonstrating sustained operational profitability amid expanding market presence.
The company's 2025 performance was bolstered by several strategic developments, including the initiation of meaningful revenue generation from the German market and two significant acquisitions: the purchase of Botanico Ltd. and a 28% equity stake in Cannasoul R&D Ltd. Additionally, InterCure received NIS 81 million in advance compensation payments from Israeli authorities related to war-related disruptions, providing supplementary liquidity support.
These results reflect InterCure's ability to navigate market conditions while maintaining financial discipline and generating cash despite ongoing regional challenges. The company's consistent achievement of positive half-year EBITDA and successful market diversification underscore its operational stability and strategic execution in a competitive sector.